Clinical Trials 2024: Unveiling The Potential of Combined Regional Studies in Emerging Locations
The clinical trials landscape is changing, taking a turn towards newer, more promising locations. While some researchers still prefer the safety of the known, they can’t help but acknowledge that some other regions have a quicker start up and enrolment, allowing patients to start the process as early as in 3 months’ time. For therapeutic areas such as oncology and infectious diseases, time is of tremendous essence, and could equal saving people’s lives or giving patients better quality living.
Join our 60-minute complimentary webinar to hear our expert panel discuss how we can bring a huge value to patients, doctors, and employees, through combined regional studies and a network of strategic partnerships, covering emerging locations such as: Georgia, Armenia, Uzbekistan and Ukraine.
Learning Objectives:
- Highlighting the importance of a comprehensive, streamlined clinical study management solution.
- Discussing the potential behind combined regional studies covering Georgia, Armenia, Uzbekistan and Ukraine and their influence on patient enrolment (higher, faster).
- Prioritizing a balanced workload for CRAs for high-caliber data integrity and in-depth understanding of the program.
- Supporting trials across all stages of data planning and management.
- Analysing how we can address the challenges, facilitate enhanced study timelines, and maximize sample integrity and utilization.
Speakers:
Elena Kozhinova
Senior Function Resource Manager, Bayer
With over 16 years of experience in clinical trials and site management, Elena Kozhinova is a seasoned expert in the pharmaceutical industry. Currently serving as a Senior Chapter Resource Manager at Bayer, Elena brings a wealth of expertise in analytical skills, account management, and team leadership. Previously, she held key roles including Country Team Leader for Site Management at Bayer, where she led operations, and undertook a short-term assignment as Country Head for Site Management. Prior to Bayer, Elena worked as a Senior Clinical Research Associate at Novartis, focusing on cardiology and eTMF, and as a Local Trial Manager at Novo Nordisk, managing regulatory affairs and diabetes-related trials. With a strong foundation in medical research from The Russian State Medical University, Elena’s career has been dedicated to advancing clinical research and site management in the pharmaceutical landscape.
Diana Matiashvili
Founder and CEO, Paspigioni
Moderator.
Diana Matiashvili is the founder and CEO of Paspigioni, a CRO established in 2015 in Tbilisi, Georgia. With a background in medicine, Diana leverages her expertise to ensure the company’s continuous success, setting high standards for quality and excellence. Under her leadership, Paspigioni has become a trusted name in clinical research, known for its commitment to Georgian cultural values such as respect, integrity, and problem-solving. Diana’s collaborative approach has fostered lasting relationships with clients, highlighting her dedication to professionalism and reliability. As a visionary leader, Diana continues to drive Paspigioni forward, shaping the future of the industry with her commitment to innovation and excellence.
DISCLAIMER
The views expressed during this webinar belong solely to the participants based on their experience as a business professional. These views do not represent those of the participants’ employers or other group(s) they may be affiliated with and they are not an endorsement of any solutions or services associated with a webinar including those of the Marcus Evans Group.
